216 related articles for article (PubMed ID: 27005283)
1. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir.
Borzacov LM; de Figueiredo Nicolete LD; Souza LF; Dos Santos AO; Vieira DS; Salcedo JM
Int J Infect Dis; 2016 May; 46():82-8. PubMed ID: 27005283
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Wedemeyer H; Yurdaydin C; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Weber K; Stift J; Wittkop U; Heidrich B; Mederacke I; von der Leyen H; Dienes HP; Cornberg M; Koch A; Manns MP;
Lancet Infect Dis; 2019 Mar; 19(3):275-286. PubMed ID: 30833068
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon plus adefovir versus either drug alone for hepatitis delta.
Wedemeyer H; Yurdaydìn C; Dalekos GN; Erhardt A; Çakaloğlu Y; Değertekin H; Gürel S; Zeuzem S; Zachou K; Bozkaya H; Koch A; Bock T; Dienes HP; Manns MP;
N Engl J Med; 2011 Jan; 364(4):322-31. PubMed ID: 21268724
[TBL] [Abstract][Full Text] [Related]
6. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
[TBL] [Abstract][Full Text] [Related]
7. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes.
Boglione L; D'Avolio A; Cariti G; Milia MG; Simiele M; De Nicolò A; Ghisetti V; Di Perri G
J Viral Hepat; 2013 Apr; 20(4):e11-9. PubMed ID: 23490378
[TBL] [Abstract][Full Text] [Related]
8. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
Boglione L; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
[TBL] [Abstract][Full Text] [Related]
9. Weight-based dosing regimen of peg-interferon α-2b for chronic hepatitis delta: a multicenter Romanian trial.
Gheorghe L; Iacob S; Simionov I; Vadan R; Constantinescu I; Caruntu F; Sporea I; Grigorescu M
J Gastrointestin Liver Dis; 2011 Dec; 20(4):377-82. PubMed ID: 22187703
[TBL] [Abstract][Full Text] [Related]
10. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine.
Mansour W; Ducancelle A; Le Gal F; Le Guillou-Guillemette H; Abgueguen P; Pivert A; Calès P; Gordien E; Lunel F
J Clin Virol; 2010 Jan; 47(1):97-9. PubMed ID: 19914127
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
[TBL] [Abstract][Full Text] [Related]
12. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
[TBL] [Abstract][Full Text] [Related]
13. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment.
Mederacke I; Yurdaydin C; Dalekos GN; Bremer B; Erhardt A; Cakaloglu Y; Yalcin K; Gurel S; Zeuzem S; Zachou K; Bozkaya H; Dienes HP; Manns MP; Wedemeyer H;
Antivir Ther; 2012; 17(2):305-12. PubMed ID: 22293066
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
[TBL] [Abstract][Full Text] [Related]
15. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
Erhardt A; Gerlich W; Starke C; Wend U; Donner A; Sagir A; Heintges T; Häussinger D
Liver Int; 2006 Sep; 26(7):805-10. PubMed ID: 16911462
[TBL] [Abstract][Full Text] [Related]
17. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of Peg-interferon alpha-2a combinated with entecavir on HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads].
Zeng W; Yuan J; Liu YX; Zhang Y; Li SX; Yao SM; Lin YM; Chen CT; Zhao MF; Liu J; Liu Y; Zhou BP
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):115-8. PubMed ID: 24044216
[TBL] [Abstract][Full Text] [Related]
19. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çalişkan A; Karatayli E; Karatayli S; Bozdayi AM; Koh C; Heller T; Idilman R; Glenn JS
Hepatology; 2018 Apr; 67(4):1224-1236. PubMed ID: 29152762
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response.
Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S
Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
